Search

Your search keyword '"Tseng, Tai–Chung"' showing total 629 results
Start Over Author "Tseng, Tai–Chung"
629 results on '"Tseng, Tai–Chung"'

1. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Author

Liu, Chen-Hua, Chang, Yu-Ping, Fang, Yu-Jen, Cheng, Pin-Nan, Chen, Chi-Yi, Kao, Wei-Yu, Lin, Chih-Lin, Yang, Sheng-Shun, Shih, Yu-Lueng, Peng, Cheng-Yuan, Tsai, Ming-Chang, Huang, Shang-Chin, Su, Tung-Hung, Tseng, Tai-Chung, Liu, Chun-Jen, Chen, Pei-Jer, and Kao, Jia-Horng

Published
2024
Full Text
View/download PDF

16. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

Author

Liu, Chen‐Hua, primary, Chang, Yu‐Ping, additional, Lee, Ji‐Yuh, additional, Chen, Chi‐Yi, additional, Kao, Wei‐Yu, additional, Lin, Chih‐Lin, additional, Yang, Sheng‐Shun, additional, Shih, Yu‐Lueng, additional, Peng, Cheng‐Yuan, additional, Lee, Fu‐Jen, additional, Tsai, Ming‐Chang, additional, Huang, Shang‐Chin, additional, Su, Tung‐Hung, additional, Tseng, Tai‐Chung, additional, Liu, Chun‐Jen, additional, Chen, Pei‐Jer, additional, and Kao, Jia‐Horng, additional

Published
2024
Full Text
View/download PDF

20. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine

Author

Park, Jiyoon, Le, An K., Tseng, Tai-Chung, Yeh, Ming-Lun, Jun, Dae Won, Trinh, Huy, Wong, Grace L.H., Chen, Chien-Hung, Peng, Cheng-Yuan, Kim, Sung Eun, Oh, Hyunwoo, Kwak, Min-Sun, Cheung, Ka Shing, Toyoda, Hidenori, Hsu, Yao-Chun, Jeong, Jae Yoon, Yoon, Eileen L., Ungtrakul, Teerapat, Zhang, Jian, Xie, Qing, Ahn, Sang Bong, Enomoto, Masaru, Shim, Jae-Jun, Cunningham, Chris, Jeong, Soung Won, Cho, Yong Kyun, Ogawa, Eiichi, Huang, Rui, Lee, Dong-Hyun, Takahashi, Hirokazu, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia-Yen, Tseng, Cheng-Hao, Yasuda, Satoshi, Kozuka, Ritsuzo, Li, Jiayi, Wong, Christopher, Wong, Clifford C., Zhao, Changqing, Hoang, Joseph, Eguchi, Yuichiro, Wu, Chao, Tanaka, Yasuhito, Gane, Ed, Tanwandee, Tawesak, Cheung, Ramsey, Yuen, Man-Fung, Lee, Hyo-Suk, Yu, Ming-Lung, Kao, Jia-Horng, Yang, Hwai-I, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

23. Correction: Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Author

Lin, Meng-Ju, Su, Tung-Hung, Chen, Chieh-Chang, Wu, Wei-Kai, Hsu, Shih-Jer, Tseng, Tai-Chung, Liao, Sih-Han, Hong, Chun-Ming, Yang, Hung-Chih, Liu, Chun-Jen, Wu, Ming-Shiang, and Kao, Jia-Horng

Subjects
Microbiota (Symbiotic organisms), Broadway theater, Infection, Medical colleges, Resveratrol, Health
Abstract

Author(s): Meng-Ju Lin[sup.1], Tung-Hung Su[sup.2,3], Chieh-Chang Chen[sup.2], Wei-Kai Wu[sup.4], Shih-Jer Hsu[sup.2], Tai-Chung Tseng[sup.2,3,4], Sih-Han Liao[sup.5], Chun-Ming Hong[sup.6], Hung-Chih Yang[sup.2], Chun-Jen Liu[sup.2,3,7], Ming-Shiang Wu[sup.2] and Jia-Horng Kao[sup.2,3,4,7] Correction: Gut Pathogens (2023) [...]

Published
2023
Full Text
View/download PDF

24. Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus

Author

Lan, Ting-Yuan, primary, Chang, Ting-Wei, additional, Tseng, Tai-Chung, additional, Lee, Tai-Ju, additional, Kao, Jui-Hung, additional, Cheng, Chiao-Feng, additional, Huang, Shang-Chin, additional, Shen, Chieh-Yu, additional, Lu, Cheng-Hsun, additional, Yang, Hung-Chih, additional, Li, Ko-Jen, additional, and Hsieh, Song-Chou, additional

Published
2024
Full Text
View/download PDF

25. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antivirals

Author

Liu, Chen-Hua, primary, Chang, Yu-Ping, additional, Lee, Ji-Yuh, additional, Chen, Chi-Yi, additional, Kao, Wei-Yu, additional, Lin, Chih-Lin, additional, Yang, Sheng-Shun, additional, Shih, Yu-Lueng, additional, Peng, Cheng-Yuan, additional, Lee, Fu-Jen, additional, Tsai, Ming-Chang, additional, Huang, Shang-Chin, additional, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Liu, Chun-Jen, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2024
Full Text
View/download PDF

31. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

Author

Liu, Matt, Tseng, Tai-Chung, Jun, Dae Won, Yeh, Ming-Lun, Trinh, Huy, Wong, Grace L. H., Chen, Chien-Hung, Peng, Cheng-Yuan, Kim, Sung Eun, Oh, Hyunwoo, Kwak, Min-Sun, Cheung, Michael, Toyoda, Hidenori, Hsu, Yao-Chun, Jeong, Jae Yoon, Yoon, Eileen L., Ungtrakul, Teerapat, Zhang, Jian, Xie, Qing, Ahn, Sang Bong, Enomoto, Masaru, Shim, Jae-Jun, Cunningham, Chris, Jeong, Soung Won, Cho, Yong Kyun, Ogawa, Eiichi, Huang, Rui, Lee, Dong-Hyun, Takahashi, Hirokazu, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia-Yen, Tseng, Cheng-Hao, Yasuda, Satoshi, Kozuka, Ritsuzo, Li, Jiayi, Wong, Christopher, Wong, Clifford C., Zhao, Changqing, Hoang, Joseph, Eguchi, Yuichiro, Wu, Chao, Tanaka, Yasuhito, Gane, Ed, Tanwandee, Tawesak, Cheung, Ramsey, Yuen, Man-Fung, Lee, Hyo-Suk, Yu, Ming-Lung, Kao, Jia-Horng, Yang, Hwai-I., and Nguyen, Mindie H.

Published
2021
Full Text
View/download PDF

32. Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping.

Author

Chang, Yu‐Ping, Huang, Chiuan‐Bo, Su, Tung‐Hung, Liu, Chun‐Jen, Tseng, Tai‐Chung, Huang, Shang‐Chin, Chen, Pei‐Jer, Kao, Jia‐Horng, and Liu, Chen‐Hua

Subjects
HEPATITIS C virus, GENOTYPES, NUCLEOTIDE sequencing, VIRAL load
Abstract

Comparison of diagnostic accuracy for commercial hepatitis C virus (HCV) genotyping (Abbott RealTime HCV Genotyping II, Roche Cobas Genotyping) and investigational Abbott HCV Genotype plus RUO assays designed to discriminate genotype (GT)‐1a, 1b or 6 in cases of ambiguous GT from the Abbott commercial assay remains limited. 743 HCV‐viremic samples were subjected to analysis using Abbott and Roche commercial as well as Abbott HCV Genotype plus RUO assays. Next‐generation sequencing (NGS) targeting core region was employed as the reference standard. Diagnostic accuracy was reported as the number of participants (percentages) along with 95% confidence intervals (CIs). Using NGS, 741 samples (99.7%) yielded valid genotyping results. The diagnostic accuracies were 97.6% (95% CI: 96.1%–98.5%) and 95.3% (95% CI: 93.4%–96.6%) using Abbott and Roche commercial assays (p = 0.0174). Abbott commercial assay accurately diagnosed HCV GT‐6a and 6w, whereas Roche commercial assay accurately diagnosed HCV GT‐6a. Both assays demonstrated low accuracies for HCV GT‐6b, 6e, 6g, and 6n. Abbott HCV Genotype plus RUO assay discriminated 13 of the 14 samples (92.9%; 95% CI: 64.2%–99.6%) that yielded ambiguous GT. Both assays were capable of diagnosing mixed HCV infections when the minor genotype comprised >8.4% of the viral load. The diagnostic performance of commercial HCV genotyping assays is commendable. Abbott assay demonstrated superior performance compared to Roche assay in diagnosing HCV GT‐6. Abbott HCV Genotype plus RUO assay aids in discriminating ambiguous GT. Both commercial assays are proficient in diagnosing mixed HCV infections at a cut‐off viral load of 8.4% in minor genotype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion

Author

Huang, Shang-Chin, primary, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Chen, Chi-Ling, additional, Hsu, Shih-Jer, additional, Liu, Chen-Hua, additional, Liao, Sih-Han, additional, Hong, Chun-Ming, additional, Lan, Ting-Yuan, additional, Yang, Hung-Chih, additional, Liu, Chun-Jen, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2023
Full Text
View/download PDF

36. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis

Author

Yeo, Yee Hui, Ho, Hsiu J., Yang, Hwai-I, Tseng, Tai-Chung, Hosaka, Tetsuya, Trinh, Huy N., Kwak, Min-Sun, Park, Young Min, Fung, James Yan Yue, Buti, Maria, Rodríguez, Manuel, Treeprasertsuk, Sombat, Preda, Carmen Monica, Ungtrakul, Teerapat, Charatcharoenwitthaya, Phunchai, Li, Xiangyong, Li, Jiayi, Zhang, Jian, Le, Michael Huan, Wei, Bin, Zou, Biyao, Le, An, Jeong, Donghak, Chien, Nicholas, Kam, Leslie, Lee, Chiao-Chin, Riveiro-Barciela, Mar, Istratescu, Doina, Sriprayoon, Tassanee, Chong, Yutian, Tanwandee, Tawesak, Kobayashi, Mariko, Suzuki, Fumitaka, Yuen, Man-Fung, Lee, Hyo-Suk, Kao, Jia-Horng, Lok, Anna S., Wu, Chun-Ying, and Nguyen, Mindie H.

Published
2019
Full Text
View/download PDF

38. Serum RNase L levels in patients with chronic hepatitis B virus infection.

Author

Chen, Chi‐Ling, Tseng, Tai‐Chung, Liu, Chun‐Jen, Kao, Jia‐Horng, Chen, Pei‐Jer, and Yang, Wei‐Shiung

Subjects
*HEPATITIS B, *CHRONIC hepatitis B, *HEPATITIS B virus, *CIRRHOSIS of the liver
Abstract

Background/Aims: Chronic hepatitis B virus (HBV) infection still poses a major threat to global health. Oligoadenylate synthetase–ribonuclease L (RNase L) antiviral pathway is one of interferon‐induced antiviral effectors. The relationship between RNase L and HBV has never been investigated and we aim to examine the serum RNase L levels in patients with different stages of chronic HBV infection. Methods: The patients were enrolled from 1985 to 2000, who had been HBsAg positive for longer than 6 months, at the National Taiwan University Hospital. In total, 426 patients with chronic HBV infection were included in this study, including 135 inactive carriers, 148 cirrhosis, and 143 hepatocellular carcinoma (HCC) cases. Results: The RNase L levels increase as the disease severity increases. Higher RNase L levels were associated with higher HBV viral load, and the HBV‐RNase L relationship was replaced by the disease severity status when adding disease status into the model. Compared with inactive carriers, the risk of liver cirrhosis was 60‐fold (odds ratio = 60.8, 95% confidence interval = 3.49–1061) with the highest quintile of RNase L levels, after the adjustment of HBV DNA. The dose–response trend was statistically significant with quintiles and one increment of RNase L level in relation to liver cirrhosis. Similar results were found when HCC was compared with inactive carriers, while there was no association when compared between liver cirrhosis and HCC. Conclusions: A positive relationship between serum RNase L and HBV viral titers or advanced disease status is uncovered in this study. Further investigation in this area may provide more details of an innate immune response for HBV and opportunity for novel therapeutic strategy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months

Author

Su, Tung‐Hung, primary, Chang, Shan‐Han, additional, Chen, Chi‐Ling, additional, Liao, Sih‐Han, additional, Tseng, Tai‐Chung, additional, Hsu, Shih‐Jer, additional, Hong, Chun‐Ming, additional, Liu, Chen‐Hua, additional, Yang, Hung‐Chih, additional, Liu, Chun‐Jen, additional, Chen, Pei‐Jer, additional, and Kao, Jia‐Horng, additional

Published
2023
Full Text
View/download PDF

45. Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria.

Author

Huang, Chian-Tzu, Chu, Yu-Long, Su, Tung-Hung, Huang, Shang-Chin, Tseng, Tai-Chung, Hsu, Shih-Jer, Liao, Sih-Han, Hong, Chun-Ming, Liu, Chen-Hua, Yang, Hung-Chih, Liu, Chun-Jen, Chen, Pei-Jer, and Kao, Jia-Horng

Subjects
LIVER cancer, HEPATOCELLULAR carcinoma, SURGICAL excision, TUMOR classification, CHEMOEMBOLIZATION, LIVER surgery
Abstract

Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC)-A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened, and those who received transarterial chemoembolization (TACE) or SR were consecutively included. The tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7–11), or high (>11). Multivariable Cox proportional hazard regression analysis was used for outcome prediction. Results: Overall, 474 patients who received SR (n = 247) and TACE (n = 227) were enrolled. Patients who underwent SR were significantly younger with better liver reserve. There were 76 (31%) and 129 (57%) deaths in the SR and TACE groups after a median follow-up of 3.9 and 2.1 years, respectively. The seven-eleven criteria could distinguish median overall survival (OS) among low (n = 149), intermediate (n = 203), and high (n = 122) tumor burden groups (7.7 vs. 6.9 vs. 2.8 years, respectively, p < 0.001). Patients receiving SR had a significantly higher median OS compared with TACE in those with intermediate (8.2 vs. 2.6 years, p < 0.001) and high (5.6 vs. 1.5 years, p = 0.001) tumor burden. After adjustment for age, sex, and liver reserve, SR was predictive for better OS in intermediate (adjusted hazard ratio [aHR]: 0.45, 95% confidence interval [CI]: 0.27–0.75) and high tumor burden groups (aHR: 0.54, 95% CI: 0.32–0.92). The survival benefit of SR especially confines to patients within 3 tumors. Conclusions: In patients with BCLC-A/B HCC beyond the Milan criteria with tumor burden beyond the up-to-7 criteria but within 3 tumors, SR has better OS than TACE and should be considered in resectable patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients

Author

Yeo, Yee Hui, Tseng, Tai-Chung, Hosaka, Tetsuya, Cunningham, Chris, Fung, James Yan Yue, Ho, Hsiu J., Kwak, Min-Sun, Trinh, Huy N., Ungtrakul, Teerapat, Yu, Ming-Lung, Kobayashi, Mariko, Le, An K., Henry, Linda, Li, Jiayi, Zhang, Jian, Sriprayoon, Tassanee, Jeong, Donghak, Tanwandee, Tawesak, Gane, Ed, Cheung, Ramsey C., Wu, Chun-Ying, Lok, Anna S., Lee, Hyo-Suk, Suzuki, Fumitaka, Yuen, Man-Fung, Kao, Jia-Horng, Yang, Hwai-I, and Nguyen, Mindie H.

Published
2020
Full Text
View/download PDF

47. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

Author

Rivino, Laura, Bert, Nina Le, Gill, Upkar S., Kunasegaran, Kamini, Cheng, Yang, Tan, Damien Z.M., Becht, Etienne, Hansi, Navjyot K., Foster, Graham R., Su, Tung-Hung, Tseng, Tai-Chung, Lim, Seng Gee, Kao, Jia-Horng, Newell, Evan W., Kennedy, Patrick T.F., and Bertoletti, Antonio

Subjects
Hepatitis B -- Care and treatment, T cells -- Health aspects, Health care industry
Abstract

BACKGROUND. The clinical management of chronic hepatitis B virus (HBV) patients is based exclusively on virological parameters that cannot independently determine in which patients nucleos(t)ide-analogue (NUC) therapy can be safely discontinued. NUCs efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation can be associated with virological and biochemical relapse and, consequently, therapy in the majority is life-long. METHODS. Since antiviral immunity is pivotal for HBV control, we investigated potential biomarkers for the safe discontinuation of NUCs within immune profiles of chronic HBV patients by utilizing traditional immunological assays (ELISPOT, flow cytometry) in conjunction with analyses of global non-antigen- specific immune populations (NanoString and CyTOF). Two distinct cohorts of 19 and 27 chronic HBV patients, respectively, were analyzed longitudinally prior to and after discontinuation of 2 different NUC therapy strategies. RESULTS. Absence of hepatic flares following discontinuation of NUC treatment correlated with the presence, during NUC viral suppression, of HBV core and polymerase-specific T cells that were contained within the ex vivo PD-1* population. CONCLUSIONS. This study identifies the presence of functional HBV-specific T cells as a candidate immunological biomarker for safe therapy discontinuation in chronic HBV patients. Furthermore, the persistent and functional antiviral activity of PD-[1.sup.+] HBV-specific T cells highlights the potential beneficial role of the expression of T cell exhaustion markers during human chronic viral infection. FUNDING. This work was funded by a Singapore Translational Research Investigator Award (NMRC/STaR/013/2012), the Eradication of HBV TCR Program (NMRC/TCR/014-NUHS/2015), the Singapore Immunology Network, the Wellcome Trust (107389/Z/15/Z), and a Barts and The London Charity (723/1795) grant., Introduction Hepatitis B virus (HBV) remains a major global healthcare challenge, with over 400 million chronically infected worldwide (1). HBV is a DNA virus that infects hepatocytes and establishes a [...]

Published
2018
Full Text
View/download PDF

48. Clinical Characteristics, Genetic Features, and Long-Term Outcome of Wilson’s Disease in a Taiwanese Population: An 11-Year Follow-Up Study

Author

Fan, Sung-Pin, primary, Kuo, Yih-Chih, additional, Lee, Ni-Chung, additional, Chien, Yin-Hsiu, additional, Hwu, Wuh-Liang, additional, Huang, Yu-Hsuan, additional, Lin, Han-I, additional, Tseng, Tai-Chung, additional, Su, Tung-Hung, additional, Tzeng, Shiou-Ru, additional, Hsu, Chien-Ting, additional, Chen, Huey-Ling, additional, Lin, Chin-Hsien, additional, and Ni, Yen-Hsuan, additional

Published
2023
Full Text
View/download PDF

50. Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals

Author

Liu, Chen-Hua, primary, Chen, Yih-Sharng, additional, Tsai, Meng-Kun, additional, Wang, Sheoi-Shen, additional, Lee, Chih-Yuan, additional, Tsao, Chuan-I, additional, Liu, Chun-Jen, additional, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Huang, Shang-Chin, additional, Wu, Jo-Hsuan, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results